Roddie, C., Leandro, M., Parker, B., Tholouli, E., Jayne, D., Uttenthal, B., Cortés-Hernández, J., Barba, P., Ivorra, J. A. R., Hu, Y., Brugger, W., Basilico, S., Germano, D., Pepper, R. (2025). Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results. Blood. https://doi.org/10.1182/blood-2025-815